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Mediastinal lymph node carcinoma of unknown primary site is rare and may have a better prognosis 
if extensive treatment is performed.  Case,  A 69-year-old-male presented with a persistent cough.  Chest 
computed tomography (CT) demonstrated a large tumor 9.5×8.2cm,  in the mediastinum,  compressing 
the right main bronchus,  the right pulmonary artery,  and the superior vena cava.  Because ﬁberoptic 
bronchoscopy was insuﬃcient for diagnosis,  mediastinoscopic tumor biopsy under general anesthesia 
was undertaken.  Histological examination revealed adenocarcinoma.  Extensive examinations revealed 
no other neoplastic lesion except in the mediastinum.  Mediastinal lymph node carcinoma of unknown 
primary site was diagnosed.  The patient was treated with docetaxel and cisplatin with concurrent 
thoracic radiation therapy.  A month after the start of chemoradiotherapy,  the mediastinal tumor 
regressed markedly.  The patient remained free of symptoms without regrowth of the primary site.  
Exploration of the body showed no further abnormalities 20 months after disease onset.
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ediastinal lymph node carcinoma of unknown 
primary site is a rare disorder.  There are 
several case reports describing patients treated by 
surgical resection,  but cases treated by chemoradio-
therapy have seldom been reported.  Therefore,  the 
usefulness of chemoradiotherapy in this disease 
remains to be determined.  We report here a patient 
with mediastinal lymph node carcinoma of unknown 
primary site successfully treated by chemoradiother-
apy.  The purpose of this report is to draw attention 
to the potential usefulness of chemoradiotherapy for 
its treatment.
Case Report
　 A 69-year-old Japanese man was referred to our 
hospital on March 14th 2008 because of an abnormal 
mass in the right pulmonary hilum.  The patient 
described a persistent cough of 1 month duration and 
a chest pain of a week.  He had a 94 pack-year smoking 
history.  He had a 20-year history of hypertension,  
hemorrhoids at the age of 64,  and disc herniation at 
59.
　 Physical examination at his ﬁrst visit showed no 
abnormalities in the chest and abdomen.  The chest 
roentgenogram at his ﬁrst visit showed a right hilar 
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mass 9.2×2.5cm.  Computed tomography (CT) of the 
chest revealed a mediastinal tumor mass measuring 
9.5×8.2cm compressing the trachea,  the right main 
bronchus,  the pulmonary artery,  and the superior 
vena cava (Fig.  1).  Computed tomography-supported 
positron emission tomography showed increased ﬂuo-
rodeoxyglucose retention in the mediastinum (maxi-
mum standard uptake values (SUV max 13.8) and a 
right supraclavicular lymph node (SUV max 4.5) (Fig.  
2).  The serum examination showed an elevated level 
of carcinoembryonic antigen,  7.8ng/ml.
　 Fiberoptic bronchoscopy showed extrinsic com-
pression and deformity of the trachea and the right 
main bronchus.  The bronchial mucosa was intact.  No 
endoluminal mass was present.  Transbronchial needle 
aspiration of the subcarina node was insuﬃcient for 
diagnosis.  The patient underwent mediastinoscopic 
examination,  and a tumor biopsy was performed.  
Microscopically,  the tumor cells replaced most of the 
lymph node,  showing a solid growth pattern and occa-
sionally formed palisading arrangements.  The tumor 
cells have a slightly eosinophilic cytoplasm and eccen-
tric round pleomorphic nuclei and small nucleoli.  
There was anisonucleosis (Fig.  3).  No mucinous cells 
were detected by PAS or Alucian blue staining.  In the 
immunohistochemical study,  tumor cells stained posi-
tive for cytokeratin and AE1/AE3 and negative for 
chromogranin A or synaptophysin.  A small number of 
cells were positive for CEA.  Pathological diagnosis 
was adenocarcinoma of the thoracic lymph node.
　 The mediastinal mass had a clear margin separated 
from the lung parenchyma,  and there was no sign of 
pleural eﬀusion; it therefore seemed unlikely that lung 
cancer had invaded the adjacent mediastinum (T4N3M0).  
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Fig. 1　 Chest CT showing the mediastinal mass compressing 
superior vena cava,  trachea,  and main bronchi.  Scale divisions 
represent 1cm each.
Fig. 2　 An image of whole-body ﬂuorodeoxyglucose-positron 
emission tomography demonstrating high uptake in the mediastinal 
region and a right supraclavicular lymph node.
Fig. 3　 Microscopic ﬁndings of resected mediastinal lymph node 
showing a solid growth pattern of tumor cells replacing the lymph 
node without recognizable gland formation.  Adenocarcionoma was 
diagnosed.  (hematoxylin-eosin; scale bar indicates 50µm)
Despite the extensive diagnostic work-up,  including 
gastroscopic and colonoscopic examinations,  enhanced 
CT of the body,  and PET/CT,  no primary cancer site 
was detected.  Mediastinal lymph node carcinoma of 
unknown primary site was diagnosed.
　 The patient had been treated with a protocol for 
lung cancer with external beam radiation to the thorax 
and chemotherapy with cisplatin and docetaxel [1].  
Both docetaxel 40mg/m2 and cisplatin 40mg/m2 were 
given on days 1,  8,  29,  and 36.  Beginning on day 1 
of chemotherapy,  thoracic radiation therapy was given 
at a total dose of 61.4 Gy over 6 weeks.  A month 
after the start of chemoradiotherapy,  the mediastinal 
tumor regressed markedly (Fig.  4).  Grade 3 granulo-
cytopenia was observed on day 12,  and recombinant 
human granulocyte colony stimulating factor was 
administered.  Reticular shadow,  compatible with 
radiation pneumonitis,  was observed in the right 
upper lung ﬁeld on chest CT 86 days after the start of 
chemoradiation therapy.  Because the patient noted a 
high fever with elevated serum CRP levels,  methyl-
prednisolone,  500mg/day,  was administered for 3 
days for the treatment of radiation pneumonitis and 
was tapered gradually.
　 The patient remained free of symptoms without 
regrowth of the primary site 22 months after disease 
onset,  and exploration of the body with enhanced CT 
or PET showed no further abnormalities.
Discussion
　 It has been reported that metastatic cancers of 
unknown primary tumor comprise 0.6-6.7ｵ of all 
cancers [2-4].
　 Greager et al.  studied 286 cases of primary 
unknown cancer and reported that the major sites of 
metastasis are lymph nodes [5].  However,  metastatic 
cancer in the thoracic lymph nodes from unknown 
primary site is a rare disorder [6] and has seldom 
been reported in English [7-11].
　 Several hypotheses regarding the development of 
primary unknown cancer are possible.  One possibility 
is that the primary site of the cancer is the lymph 
node.  It is a well-known fact that benign epithelial 
inclusions exist in cervical [12,  13],  pelvic and peri-
toneal [14,  15],  and axillary lymph nodes [16-18].  
Neoplastic cells in lymph nodes may have resulted 
from the transformation of ectopic epithelial inclu-
sions.  In fact,  there has been a report describing a 
carcinoma that originated from benign epithelial inclu-
sion in an axillary lymph node [19].  The second 
hypothesis is that the primary is too small to be 
detected by our means of the clinical investigation.  
Recent advances in diagnostic techniques such as high-
resolution CT or PET/CT enable us to detect very 
small cancer lesions,  making the possibility of an 
occult primary site very low.  However,  the possibility 
of an occult primary site could not be denied even after 
an extensive radiological or endoscopical workup.  The 
third hypothesis is that the spontaneous regression of 
primary cancer lesion occurred,  while the metastatic 
lesion remained intact.  The host immunologic mecha-
nism might destroy a small primary tumor but fail to 
destroy an established metastatic tumor.  It has been 
reported that spontaneous regression occurs no more 
than once in 60,000-100,000 cancer cases [20].  The 
incidence of spontaneous regression is extremely low 
compared to that of cancer of unknown primary site,  
0.6-6.7ｵ of all cancers,  as described previously,  and 
we could not explain the pathogenesis of cancer of 
unknown primary based on this hypothesis alone.
　 Although it is not widely accepted,  the most prob-
able hypothesis seems to be that neoplastic cells arise 
from endogenous epithelium in the lymph node.
　 The term T0N2M0 lung cancer has been used as a 
synonym of mediastinal lymph node carcinoma of 
unknown primary site.  However,  the possibility of the 
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Fig. 4　 Chest CT,  a month after the start of chemotherapy,  
showing a markedly regressed mediastinal tumor.  Scale divisions 
represent 1cm each.
endogenous cancer origin in the mediastinal node has 
not been ruled out,  as described previously,  and the 
most widely accepted term currently in use,  and that 
we adopt here,  is ʻMediastinal lymph node carcinoma 
of unknown primary site. ʼ
　 Miyoshi has reported 70 cases of mediastinal lymph 
node carcinoma of an unknown primary site in Japan 
[21].  In the study group,  a male predominance was 
seen.  The age ranged from 5 to 85 years with a 
median age of 57.7 years.  The most frequent histology 
type was adenocarcinoma in 41ｵ of patients,  followed 
by small cell carcinoma in 19ｵ,  large cell carcinoma 
in 17ｵ,  and squamous cell carcinoma in 16ｵ.
　 In general,  it appears that patients with cancer of 
an unknown primary site have a limited life expectancy 
with a median survival of 6-9 months [22].  However,  
when limiting such cases to mediastinal lymph node 
carcinoma,  the survival period is far longer [11].  It 
is suggested that surgical resection of the mediastinal 
lymph node should be the ﬁrst treatment of choice 
because the best survival beneﬁt is obtained by com-
plete dissection of the tumor [6,  11].  There are some 
papers suggesting that radical resection of mediastinal 
lymph node carcinoma either combined with chemo-
therapy or radiation therapy may oﬀer a chance of 
cure and may increase long-term survival [6,  11,  21,  
23,  24].  In our patient,  complete excision of the 
mediastinal tumor was diﬃcult,  and supraclavicular 
involvement was prominent.
　 There have been only a few reports showing the 
eﬀectiveness of chemoradiotherapy in the treatment of 
mediastinal lymph node carcinoma from an unknown 
origin.  It has been reported that patients with medi-
astinal lymph node carcinoma from unknown origin do 
poorly when treated only medically [25].  On the other 
hand,  Miwa et al.  have reported two cases of medi-
astinal lymph node carcinoma treated by chemoradio-
therapy.  Both cases were alive 33 and 24 months,  
respectively [11].  Watanabe et al.  also reported a 
case of carcinoma of unknown primary site with 
involvement of the mediastinal lymph node that was 
successfully treated by chemotherapy with carboplatin 
and paclitaxel followed by sequential radiation ther-
apy [26].  This protocol is designed for nonsmall cell 
lung cancer.  These reports suggest the potential 
usefulness of chemoradiation therapy for mediastinal 
lymph node carcinoma of unknown primary site.  Kiura 
et al.  have reported promising treatment results of 
docetaxel and cisplatin with radiation therapy for 
nonsmall cell lung cancer [1].  In the study,  the over-
all response rate was 79ｵ and the survival rate was 
54ｵ at 2 years.  We have therefore chosen to treat 
the patient with this protocol,  and he is still alive 22 
months after the diagnosis.
　 In conclusion,  it is suggested that appropriate 
chemoradiotherapy for mediastinal lymph node carci-
noma of an unknown primary site may oﬀer a chance 
of long-term survival in patients who are not eligible 
for radical exsection.
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